Navigation Links
Oridion Announces Major Medical Research and Congress Presentations
Date:6/16/2008

JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were recently presented at medical congresses in the United States and Europe.

During Digestive Disease Week (DDW) in San Diego, California, Dr. Vargo, of the Cleveland Clinic, presented a blinded study that analyzed 122 randomized patients and showed that Microstream(R) capnography "significantly reduces the proportion of patients with hypoxemia, major hypoxemia, apnea and oxygen requirements during ERCP (Endoscopic Retrograde Cholangiopancreatography) and EUS (Endoscopic ultrasound).

Other studies describing the clinical value of Microstream(R) EtCO2 monitoring were presented during the European Resuscitation Council (ERC) in Ghent, Belgium and the European Society of Anesthesiology (ESA) in Copenhagen, Denmark. At ERC, two oral presentations were given and a Capnography Symposium took place with three distinguished clinicians and the clinical practice manager from London Ambulance Service. The four presentations showed the value of capnography in pre-hospital care (trauma, intubations, and ROSC). The Symposium was moderated by Prof. Pierre Carli, President Societe Francaise d'Anesthesie et de Reanimation (French Society of Anesthesia and Intensive Care).

Two medical presentations given at European Society of Anesthesia demonstrated the importance of capnography for non-intubated and intubated patients. In a study on the use of continuous non-invasive arterial CO2 estimation in spontaneously breathing patients after craniotomy, Dr. Wolter from France showed a good correlation between capnography and arterial blood gas analysis in sedated patients under regional anesthesia.

"These recent studies continue to confirm that patients are safer when their caregivers use Oridion Microstream(R) capnography technology," stated Gerry Feldman, President of Oridion Capnography. "The results of these global research projects clearly demonstrate that capnography improves patient safety and should be included in hospital and pre-hospital ventilatory monitoring strategies."

Oridion is the global leader of innovative capnography monitoring solutions helping to improve patient safety, and its Microstream(R) capnography technology has become the standard of care in ventilation monitoring.

A full list of these medical abstracts can be found on the Oridion website: http://www.oridion.com/global/english/clinical_solutions/overview/research. ht ml.
Next financial reporting:

August 18, 2008 Results Q2 / Half Year 2008

November 10, 2008 Results Q3 / Nine Months 2008

About Oridion Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, factors effecting OEM partners' position in the market, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

For further information please contact:

Alan Adler, Chairman and Chief Executive Officer

Gerry Feldman, President

Walter Tabachnik, Chief Financial Officer

Elena Gerberg, Investor Relations

e-mail: investor@oridion.com

website : http://www.oridion.com

phone : +972-2-589-9159

address : Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel


'/>"/>
SOURCE Oridion Systems Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):